Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)NCT07108010
ABO and Rh Blood Group Frequencies in Acute Leukemia Patients
An observational study of Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia), run by Assiut University at 1 site in Egypt.
Trial summary
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia. By analyzing medical records from leukemia cases, the study seeks to identify any potential associations between blood group types and the occurrence of the disease. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Oct 2025to 28 Apr 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients diagnosed with de-novo acute leukemia (ALL and AML) at South Egypt Cancer Institute, Assiut University, during the period from 2022 to 2025.
Who may be able to join
- Patients diagnosed with de-novo acute leukemia (ALL or AML)
- Diagnosis confirmed between 2022 and 2025
- ABO and Rh blood group data available
- Patients treated at or referred to South Egypt Cancer Institute, Assiut University
Who cannot join
- Incomplete or missing blood group data
- Presence of other malignancies or chronic systemic illnesses
- History of blood transfusion prior to diagnosis or blood grouping
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Aisha Abobakr Abass Metwally, M.B.B.Ch., M.Sc. (Candidate) contact
About this study
Official title: Evaluation of ABO and Rh Blood Group Frequencies in Acute Leukemia
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia. By analyzing medical records from leukemia cases, the study seeks to identify any potential associations between blood group types and the occurrence of the disease.
Read the detailed description
Acute leukemia is a group of hematologic malignancies characterized by the rapid proliferation of immature blood cells, leading to bone marrow failure and systemic complications. It is broadly classified into two main types: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), depending on the lineage of the malignant cells. Despite advancements in the understanding of leukemia pathogenesis, the etiology remains multifactorial and incompletely understood.
Recent studies have suggested a potential association between blood group antigens-particularly those of the ABO and Rh systems-and the risk of developing various types of cancer, including hematological malignancies. The ABO antigens are expressed not only on red blood cells but also on epithelial and endothelial cells, and may influence cancer biology through mechanisms involving immune response modulation, cell adhesion, and inflammation.
Several epidemiological investigations have explored the relationship between ABO and Rh blood groups and malignancies such as gastric, pancreatic, breast, and hematologic cancers. However, data regarding their association with acute leukemia are still limited, inconsistent, and often vary across different populations and study designs.
This study is a retrospective observational analysis conducted at the Clinical Pathology Department, South Egypt Cancer Institute, Assiut University. It aims to assess the frequencies of ABO and Rh blood groups among patients diagnosed with acute leukemia over a defined period. The findings will be compared to blood group distributions in healthy blood donors to explore any statistically significant associations.
Understanding whether certain blood group antigens are associated with an increased or decreased risk of acute leukemia may help identify at-risk individuals, contribute to risk stratification, and provide further insight into the biology of leukemogenesis.
- Keywords
- Acute Leukemia, ABO Blood Group and Rh Blood Group, Hematologic Malignancies, Retrospective Study
- Medical subject headings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematologic Neoplasms
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency distribution of ABO and Rh blood groups among acute leukemia patients
Assessment of the percentage of each ABO and Rh blood group among patients diagnosed with acute leukemia (including ALL and AML) using retrospectively collected data from blood bank records and clinical files at South Egypt Cancer Institute.
Measured: Between 2022 and 2025
Secondary outcomes (1)
Association between blood group types and leukemia subtype
Evaluation of any statistically significant relationship between specific ABO/Rh blood groups and the type of leukemia (ALL vs AML).
Measured: Between 2022 and 2025
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Aug 2025
- Study start1 Oct 2025 (estimated)
- Primary completion30 Dec 2026 (estimated)
- Study completion28 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)Studies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aisha Abobakr Abass Metwally, Assiut University
- Investigators
- Asmaa Mohamed Zahran, M.D., Professor, Principal investigator, South Egypt Cancer Institute, Assiut UniversityWalaa Talaat Kamel, M.D., Lecturer, Study chair, South Egypt Cancer Institute, Assiut UniversityEsraa Nasr Abd El Hakeem, M.D., Lecturer, Study chair, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07108010
- Sponsor's protocol ID
- Blood group in Acute Leukemia
- Status last verified
- Jul 2025
- First submitted
- 31 Jul 2025
- Last updated
- 6 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of ABO and Rh Blood Group Frequencies in Acute Leukemia
- ClinicalTrials.gov ID
- NCT07108010
- Acronym / sponsor ID
- Blood group in Acute Leukemia
- Keywords
- Acute Leukemia, ABO Blood Group and Rh Blood Group, Hematologic Malignancies, Retrospective Study
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Oct 2025 (estimated)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 28 Apr 2027 (estimated)
- First posted
- 6 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This retrospective observational study aims to evaluate the distribution of ABO and Rh blood groups among patients diagnosed with acute leukemia. By analyzing medical records from leukemia cases, the study seeks to identify any potential associations between blood group types and the occurrence of the disease.
Detailed description
Acute leukemia is a group of hematologic malignancies characterized by the rapid proliferation of immature blood cells, leading to bone marrow failure and systemic complications. It is broadly classified into two main types: acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), depending on the lineage of the malignant cells. Despite advancements in the understanding of leukemia pathogenesis, the etiology remains multifactorial and incompletely understood.
Recent studies have suggested a potential association between blood group antigens-particularly those of the ABO and Rh systems-and the risk of developing various types of cancer, including hematological malignancies. The ABO antigens are expressed not only on red blood cells but also on epithelial and endothelial cells, and may influence cancer biology through mechanisms involving immune response modulation, cell adhesion, and inflammation.
Several epidemiological investigations have explored the relationship between ABO and Rh blood groups and malignancies such as gastric, pancreatic, breast, and hematologic cancers. However, data regarding their association with acute leukemia are still limited, inconsistent, and often vary across different populations and study designs.
This study is a retrospective observational analysis conducted at the Clinical Pathology Department, South Egypt Cancer Institute, Assiut University. It aims to assess the frequencies of ABO and Rh blood groups among patients diagnosed with acute leukemia over a defined period. The findings will be compared to blood group distributions in healthy blood donors to explore any statistically significant associations.
Understanding whether certain blood group antigens are associated with an increased or decreased risk of acute leukemia may help identify at-risk individuals, contribute to risk stratification, and provide further insight into the biology of leukemogenesis.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients diagnosed with de-novo acute leukemia (ALL and AML) at South Egypt Cancer Institute, Assiut University, during the period from 2022 to 2025.
Key inclusion criteria (4 listed)
- Patients diagnosed with de-novo acute leukemia (ALL or AML)
- Diagnosis confirmed between 2022 and 2025
- ABO and Rh blood group data available
- Patients treated at or referred to South Egypt Cancer Institute, Assiut University
Key exclusion criteria (3 listed)
- Incomplete or missing blood group data
- Presence of other malignancies or chronic systemic illnesses
- History of blood transfusion prior to diagnosis or blood grouping
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Frequency distribution of ABO and Rh blood groups among acute leukemia patients
Time frame: Between 2022 and 2025
Assessment of the percentage of each ABO and Rh blood group among patients diagnosed with acute leukemia (including ALL and AML) using retrospectively collected data from blood bank records and clinical files at South Egypt Cancer Institute.
1 secondary outcome
Association between blood group types and leukemia subtype
Time frame: Between 2022 and 2025
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Aug 2025.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
Related trials for Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia)
RecruitingPhase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
Neurofibroma, Plexiform, Precursor Cell Lymphoblastic Leukemia-Lymphoma
RecruitingPhase 1/2
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Active, not recruiting
Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission
RecruitingPhase 1
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Aisha Abobakr Abass Metwally, M.B.B.Ch., M.Sc. (Candidate) contact
Asmaa Mohamed Zahran, M.D., Professor principal investigator
South Egypt Cancer Institute, Assiut University
Walaa Talaat Kamel, M.D., Lecturer study chair
South Egypt Cancer Institute, Assiut University
Esraa Nasr Abd El Hakeem, M.D., Lecturer study chair
Assiut University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Leukemia (Including Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia), run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Aisha Abobakr Abass Metwally, M.B.B.Ch., M.Sc. (Candidate) (+201033766743, aishaabobakr222@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency distribution of ABO and Rh blood groups among acute leukemia patients (time frame: Between 2022 and 2025). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Aug 2025.